The Current Landscape of Early Drug Development for Patients With Sarcoma

Breelyn A Wilky, Robin L. Jones, Vicki L. Keedy

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Until recently, advancements in the treatment of patients with adult soft tissue sarcomas have been relatively slow. This is, in part, due to their heterogeneity and rarity. A better understanding of the biology and differences among the various histologies has led to substantial growth in novel strategies. In addition to novel cytotoxic chemotherapies, agents targeting platelet-derived growth factor receptor-α (PDGFRα), mTOR, and angiogenesis are areas of active investigation. Additionally, with the success of checkpoint inhibitors in other malignancies and early encouraging results of checkpoint inhibitors in some sarcoma subtypes, this approach is being widely investigated in various sarcomas. As we increasingly recognize and treat each sarcoma histology as a separate disease, it is important to spread awareness of the exciting clinical trials available to our patients with these rare malignancies.

Original languageEnglish (US)
Pages (from-to)807-810
Number of pages4
JournalAmerican Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
Volume37
DOIs
StatePublished - Jan 1 2017
Externally publishedYes

Fingerprint

Sarcoma
Pharmaceutical Preparations
Histology
Platelet-Derived Growth Factor Receptors
Cytotoxins
Neoplasms
Clinical Trials
Drug Therapy
Growth
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

The Current Landscape of Early Drug Development for Patients With Sarcoma. / Wilky, Breelyn A; Jones, Robin L.; Keedy, Vicki L.

In: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, Vol. 37, 01.01.2017, p. 807-810.

Research output: Contribution to journalReview article

@article{8fcee56fe6274493ab60bac2bf4f9f5b,
title = "The Current Landscape of Early Drug Development for Patients With Sarcoma",
abstract = "Until recently, advancements in the treatment of patients with adult soft tissue sarcomas have been relatively slow. This is, in part, due to their heterogeneity and rarity. A better understanding of the biology and differences among the various histologies has led to substantial growth in novel strategies. In addition to novel cytotoxic chemotherapies, agents targeting platelet-derived growth factor receptor-α (PDGFRα), mTOR, and angiogenesis are areas of active investigation. Additionally, with the success of checkpoint inhibitors in other malignancies and early encouraging results of checkpoint inhibitors in some sarcoma subtypes, this approach is being widely investigated in various sarcomas. As we increasingly recognize and treat each sarcoma histology as a separate disease, it is important to spread awareness of the exciting clinical trials available to our patients with these rare malignancies.",
author = "Wilky, {Breelyn A} and Jones, {Robin L.} and Keedy, {Vicki L.}",
year = "2017",
month = "1",
day = "1",
doi = "10.14694/EDBK_174701",
language = "English (US)",
volume = "37",
pages = "807--810",
journal = "American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting",
issn = "1548-8756",
publisher = "American Society of Clinical Oncology",

}

TY - JOUR

T1 - The Current Landscape of Early Drug Development for Patients With Sarcoma

AU - Wilky, Breelyn A

AU - Jones, Robin L.

AU - Keedy, Vicki L.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Until recently, advancements in the treatment of patients with adult soft tissue sarcomas have been relatively slow. This is, in part, due to their heterogeneity and rarity. A better understanding of the biology and differences among the various histologies has led to substantial growth in novel strategies. In addition to novel cytotoxic chemotherapies, agents targeting platelet-derived growth factor receptor-α (PDGFRα), mTOR, and angiogenesis are areas of active investigation. Additionally, with the success of checkpoint inhibitors in other malignancies and early encouraging results of checkpoint inhibitors in some sarcoma subtypes, this approach is being widely investigated in various sarcomas. As we increasingly recognize and treat each sarcoma histology as a separate disease, it is important to spread awareness of the exciting clinical trials available to our patients with these rare malignancies.

AB - Until recently, advancements in the treatment of patients with adult soft tissue sarcomas have been relatively slow. This is, in part, due to their heterogeneity and rarity. A better understanding of the biology and differences among the various histologies has led to substantial growth in novel strategies. In addition to novel cytotoxic chemotherapies, agents targeting platelet-derived growth factor receptor-α (PDGFRα), mTOR, and angiogenesis are areas of active investigation. Additionally, with the success of checkpoint inhibitors in other malignancies and early encouraging results of checkpoint inhibitors in some sarcoma subtypes, this approach is being widely investigated in various sarcomas. As we increasingly recognize and treat each sarcoma histology as a separate disease, it is important to spread awareness of the exciting clinical trials available to our patients with these rare malignancies.

UR - http://www.scopus.com/inward/record.url?scp=85047062528&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047062528&partnerID=8YFLogxK

U2 - 10.14694/EDBK_174701

DO - 10.14694/EDBK_174701

M3 - Review article

VL - 37

SP - 807

EP - 810

JO - American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting

JF - American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting

SN - 1548-8756

ER -